International Assets Investment Management LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

International Assets Investment Management LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, Holdings Channel.com reports. The fund purchased 6,572 shares of the medical equipment provider’s stock, valued at approximately $407,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tucker Asset Management LLC raised its position in Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares in the last quarter. First Horizon Advisors Inc. raised its position in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 225 shares in the last quarter. Covestor Ltd raised its position in Lantheus by 62.7% during the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 156 shares during the last quarter. Finally, NBC Securities Inc. acquired a new position in shares of Lantheus in the third quarter valued at $46,000. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on LNTH. Truist Financial reiterated a “buy” rating and issued a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. B. Riley upped their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.71.

Lantheus Trading Down 0.0 %

LNTH stock opened at $65.20 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The company’s 50-day simple moving average is $61.31 and its 200 day simple moving average is $62.75. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a market capitalization of $4.47 billion, a PE ratio of 14.05 and a beta of 0.53.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The business had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold 94,545 shares of company stock worth $6,169,936 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.